The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO WCGIC 2022 | Treatment landscape for cholangiocarcinoma
Lorenza Rimassa, MD, Humanitas University and IRCCS Humanitas Research Hospital, Milan, Italy, explains the basics of cholangiocarcinoma, including the incidence, survival rates, and current treatment landscape for patients with early-stage and advanced disease. Chemotherapy is a key part of treatment for patients with advanced cholangiocarcinoma, but the recent Phase III TOPAZ-1 trial (NCT03875235) reported positive results for the addition of durvalumab to first-line chemotherapy for these patients. Dr Rimassa also discusses recent research into novel targeted treatments for cholangiocarcinoma. This interview took place at the European Society for Medical Oncology World Congress on Gastrointestinal Cancer (ESMO WCGIC) 2022 in Barcelona, Spain.
